← Oncology Approval Tracker

FDA DECISION ·

Lanreotide Injection

lanreotide acetate · InvaGen Pharmaceuticals

FDA approvalNew formulationGastroenteropancreatic neuroendocrine tumors
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

Adult patients with unresectable, well or moderately differentiated, locally advanced or metastatic gastroenteropancreatic neuroendocrine tumors, to improve progression-free survival.

LAMPGEN ANALYSIS

Why it matters

This 505(b)(2) NDA approves a lanreotide injection product for an established tumor setting.

What research teams should watch

Verify the product, syringe presentation, injection technique and neuroendocrine tumor differentiation.

PRIMARY RECORDS

Sources